Immutep (ASX:IMM) has passed a key clinical milestone, achieving 50 per cent patient enrolment in its pivotal global Phase 3 trial evaluating a novel immunotherapy combination for first-line non-small cell lung cancer. …
Latest Video
New Stories
-
Sanofi volunteers confront homelessness at Vinnies CEO Sleepout
June 19, 2026 - - Latest News -
Infectious diseases across the lifespan are a hidden burden beyond the acute episode
June 19, 2026 - - Latest News -
Gilead rushes remdesivir to Uganda to support Ebola response
June 19, 2026 - - Latest News -
Rhapsido approved in Australia as first oral targeted option for chronic spontaneous urticaria
June 18, 2026 - - Latest News -
Is China's international benchmarking a bigger short-term risk to medicines access?
June 18, 2026 - - Latest News -
Life sciences leaders brace for class action wave as dispute risks multiply
June 18, 2026 - - Latest News -
Australia's life sciences sector welcomes new CGT concession but urges RDTI fixes
June 18, 2026 - - Latest News